We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+0.4%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$6.91B
AUM Growth
-$33.5M
Cap. Flow
-$96.8M
Cap. Flow %
-1.4%
Top 10 Hldgs %
55.6%
Holding
295
New
67
Increased
47
Reduced
98
Closed
74

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$81.6M
2
NVRO
NEVRO CORP.
NVRO
+$68M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$61.4M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$55.5M
5
KDP icon
Keurig Dr Pepper
KDP
+$44.2M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$105M
2
OGN icon
Organon & Co
OGN
+$75.3M
3
EXAS
Exact Sciences
EXAS
+$69M
4
BIIB icon
Biogen
BIIB
+$57.7M
5
CENTA icon
Central Garden & Pet Co Class A
CENTA
+$53.3M

Sector Composition

Rank Sector Weight
1 Healthcare 39.29%
2 Consumer Staples 5.94%
3 Technology 4.58%
4 Consumer Discretionary 4.41%
5 Communication Services 2.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$1.86B 26.94%
4,200,000
-50,000
-1% -$21M
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$80.9B
$993M 14.36%
5,300,000
+400,000
+8% +$71.3M
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.7B
$156M 2.25%
1,650,000
+58,000
+4% +$5.67M
SUPN icon
4
Supernus Pharmaceuticals
SUPN
$2.68B
$151M 2.19%
5,036,000
+686,000
+16% +$24M
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$144M 2.08%
3,978,000
+286,000
+8% +$11.8M
PTCT icon
6
PTC Therapeutics
PTCT
$6.37B
$132M 1.9%
3,236,000
+312,000
+11% +$15.3M
TVTX icon
7
Travere Therapeutics
TVTX
$5.33B
$114M 1.66%
7,450,000
+302,000
+4% +$5.49M
INCY icon
8
Incyte
INCY
$23.5B
$111M 1.6%
1,776,000
-96,000
-5% -$6.42M
AGIO icon
9
Agios Pharmaceuticals
AGIO
$2.16B
$92.2M 1.33%
3,256,000
-204,000
-6% -$5.08M
REGN icon
10
Regeneron Pharmaceuticals
REGN
$68.8B
$89.1M 1.29%
124,000
+72,000
+138% +$55.5M
ARGX icon
11
argenx
ARGX
$57.4B
$77.9M 1.13%
200,000
-24,000
-11% -$9.44M
PFE icon
12
Pfizer
PFE
$140B
$76.9M 1.11%
+2,096,000
New +$81.6M
JNJ icon
13
Johnson & Johnson
JNJ
$635B
$76.1M 1.1%
460,000
+2,117
+0.5% +$342K
MDGL icon
14
PUT
Madrigal Pharmaceuticals
MDGL
$12.6B
$73.9M 1.07%
+320,000
New +$86.7M
BIIB icon
15
Biogen
BIIB
$29.9B
$72.9M 1.06%
256,000
-194,000
-43% -$57.7M
UNH icon
16
UnitedHealth
UNH
$382B
$72.1M 1.04%
150,000
-42,000
-22% -$20.5M
XRAY icon
17
Dentsply Sirona
XRAY
$2.59B
$72M 1.04%
1,800,000
-456,000
-20% -$18.1M
FRPT icon
18
Freshpet
FRPT
$2.83B
$69.1M 1%
1,050,000
-137,000
-12% -$8.97M
AMZN icon
19
Amazon
AMZN
$2.5T
$68.3M 0.99%
524,000
-400,000
-43% -$45.7M
MDT icon
20
Medtronic
MDT
$107B
$66.6M 0.96%
756,000
+78,000
+12% +$6.72M
GOOGL icon
21
Alphabet (Google) Class A
GOOGL
$3.91T
$65.6M 0.95%
548,000
-252,000
-32% -$29M
DCPH
22
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$64.2M 0.93%
4,560,000
+460,000
+11% +$6.58M
ALKS icon
23
Alkermes
ALKS
$8.82B
$62.6M 0.91%
2,000,000
-724,000
-27% -$21.9M
NVRO
24
DELISTED
NEVRO CORP.
NVRO
$59.9M 0.87%
+2,356,000
New +$68M
JAZZ icon
25
Jazz Pharmaceuticals
JAZZ
$15.9B
$56.5M 0.82%
+456,000
New +$61.4M
1
2 3 4 5

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
DWM
Diversify Wealth Management Sandy, Utah $5.61B AUM 19.63% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
AIM
Alphinity Investment Management Sydney, Australia $5.68B AUM 26.72% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return

Armistice Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Armistice Capital held 295 positions worth $6.91B, down 0.48% from $6.94B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Armistice Capital's Q2 2023 filing shows 67 new, 47 increased, 98 reduced and 74 closed positions. Its largest new stake was Pfizer: 2,096,000 shares worth $76.9M. The largest sale was GSK, an estimated $105M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 44% a quarter earlier, followed by Consumer Staples and Technology.

  • Armistice Capital's largest Q2 2023 buy was Pfizer: 2,096,000 shares worth $76.9M.
  • Armistice Capital added most to Regeneron Pharmaceuticals in Q2 2023, an estimated $55.5M increase.
  • Armistice Capital's biggest Q2 2023 reduction was GSK, cutting an estimated $105M.
  • Armistice Capital fully exited Organon & Co in Q2 2023, selling an estimated $75.3M.
  • Armistice Capital's ten largest holdings make up 56% of its $6.91B portfolio in Q2 2023.
  • Armistice Capital opened 67 new positions and closed 74 in Q2 2023.
  • Armistice Capital's portfolio value fell 0.48% quarter-over-quarter to $6.91B.

Based on Armistice Capital's 13F filing for Q2 2023, filed 14 Aug 2023.